Latest news with #EuronextAmsterdam
Yahoo
12-06-2025
- Business
- Yahoo
Share Buyback Transaction Details June 5 – June 11, 2025
PRESS RELEASE Share Buyback Transaction Details June 5 – June 11, 2025 Alphen aan den Rijn – June 12, 2025 - Wolters Kluwer (Euronext: WKL), a global leader in professional information solutions, software and services, today reports that it has repurchased 222,303 of its own ordinary shares in the period from June 5, 2025, up to and including June 11, 2025, for €34.4 million and at an average share price of €154.85. These repurchases are part of the share buyback program announced on February 26, 2025, under which we intend to repurchase shares for up to € 1 billion during 2025. The cumulative amounts repurchased in the year to date under this program are as follows: Share Buyback 2025 Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€) 2025 to date 2,972,609 461.9 155.38 For the period starting May 8, 2025, up to and including July 28, 2025, we have engaged third parties to execute €350 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company's Articles of Association. Shares repurchased are added to and held as treasury shares and will be used for capital reduction purposes through share cancelation. Further information is available on our website: Download the share buyback transactions excel sheet for detailed individual transaction information. Weekly reports on the progress of our share repurchases. Overview of share buyback programs. For more information about Wolters Kluwer, please visit: ### About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,900 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX, Euro Stoxx 50 and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY). For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram. Media Investors/Analysts Stefan Kloet Meg Geldens Associate Director Vice President Global Communications Investor Relations press@ ir@ Forward-looking Statements and Other Important Legal InformationThis report contains forward-looking statements. These statements may be identified by words such as 'expect', 'should', 'could', 'shall' and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; conditions created by pandemics; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer's businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Elements of this press release contain or may contain inside information about Wolters Kluwer within the meaning of Article 7(1) of the Market Abuse Regulation (596/2014/EU). Trademarks referenced are owned by Wolters Kluwer N.V. and its subsidiaries and may be registered in various countries. Attachment 2025.06.12 Share Buyback Transactions Jun 5 - 11 2025Sign in to access your portfolio
Miami Herald
06-06-2025
- Business
- Miami Herald
Netherlands to vote on October 29 after government falls
The Netherlands will hold a general election on October 29 after far-right leader Geert Wilders pulled his Freedom Party out of the Dutch government earlier this week. The Minister of the Interior Judith Uitermark posted the date on X Friday. Wilders pulled the plug on the coalition after his partners rejected his latest proposals to curb immigration, plunging the European nation into months of uncertainty. A caretaker government is now in place after Prime Minister Dick Schoof tendered his resignation. The fall of the coalition will negatively impact investment and consumption, Olaf Sleijpen, the Dutch central bank's executive director of monetary affairs and financial stability, warned Friday. Even after an election is held, coalitions can take months to build, meaning the Netherlands faces a lengthy period of a government which cannot deal with the most sensitive topics. The parliament is expected to vote on a list of policy areas deemed "controversial" that the caretaker administration should avoid until after the elections. Schoof on Wednesday urged lawmakers to consider international security, tariffs and the budget among uncontroversial topics to be handled by the caretaker Cabinet. There was little reaction from the AEX Index, a gauge tracking the 25 largest stocks listed on the Euronext Amsterdam, which was trading flat as at 12:55pm CET. ---------- -With assistance from Patrick Van Oosterom. Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
Yahoo
06-06-2025
- Business
- Yahoo
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025
Vivoryon Therapeutics N.V. Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 Halle (Saale) / Munich, Germany, June 6, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that meta-analysis data for its lead drug in development, varoglutamstat, was presented at the 62nd ERA Congress of the European Renal Association in Vienna, Austria, today, June 6, 2025. 'We are delighted that the results of the Phase 2 program were accepted for presentation at the ERA 2025 congress. This allowed Vivoryon to share the outstanding improvements of varoglutamstat on kidney function (eGFR) with the scientific and medical expert community in the kidney space,' said Frank Weber, MD, CEO of Vivoryon. Presentation Highlights Varoglutamstat is a first-in-class glutaminyl cyclase (QPCT/L) inhibitor with potent anti-inflammatory and anti-fibrotic effects. VIVIAD and VIVA-MIND, two independent Phase 2 studies in the EU and U.S. showed a statistically significant and clinically meaningful improvement in a prospectively defined kidney function parameter, eGFR, in an elderly patient population. This improvement was consistent in both trials independently, replicated in the meta-analysis and pooled analysis, and provides converging evidence for this finding. Statistically significant differences between varoglutamstat and placebo were first observed at week 24 and were sustained until week 96. The meta-analysis also confirmed a substantially larger effect size in study participants with diabetes compared to those without diabetes. The next step is planned to be a dedicated Phase 2b trial in patients with diabetic kidney disease (patients with diabetes and chronic kidney disease stage 3b/4). The main goal will be to investigate the efficacy on eGFR in this patient population and to obtain additional information on a potential effect on proteinuria and other kidney specific markers. Presentation Details Date: June 6, 2025 Presentation time: 8:15 am CEST as part of the focused oral session Title: Varoglutamstat improves eGFR and offers a new approach to treat diabetic kidney disease (DKD): meta-analysis from two independent Phase 2 studies Venue: Vienna, Austria Presenter: Frank Weber, MD, CEO of Vivoryon Therapeutics ### About Vivoryon Therapeutics N.V. Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon's most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease.
Yahoo
05-06-2025
- Business
- Yahoo
Share Buyback Transaction Details May 29 – June 4, 2025
PRESS RELEASE Share Buyback Transaction Details May 29 – June 4, 2025 Alphen aan den Rijn – June 5, 2025 - Wolters Kluwer (Euronext: WKL), a global leader in professional information solutions, software and services, today reports that it has repurchased 225,452 of its own ordinary shares in the period from May 29, 2025, up to and including June 4, 2025, for €35.2 million and at an average share price of €155.93. These repurchases are part of the share buyback program announced on February 26, 2025, under which we intend to repurchase shares for up to € 1 billion during 2025. The cumulative amounts repurchased in the year to date under this program are as follows: Share Buyback 2025 Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€) 2025 to date 2,750,306 427.5 155.43 For the period starting May 8, 2025, up to and including July 28, 2025, we have engaged third parties to execute €350 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company's Articles of Association. Shares repurchased are added to and held as treasury shares and will be used for capital reduction purposes through share cancelation. Further information is available on our website: Download the share buyback transactions excel sheet for detailed individual transaction information. Weekly reports on the progress of our share repurchases. Overview of share buyback programs. For more information about Wolters Kluwer, please visit: ### About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX, Euro Stoxx 50 and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY). For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram. Media Investors/Analysts Stefan Kloet Meg Geldens Associate Director Vice President Global Communications Investor Relations press@ ir@ Forward-looking Statements and Other Important Legal InformationThis report contains forward-looking statements. These statements may be identified by words such as 'expect', 'should', 'could', 'shall' and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; conditions created by pandemics; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer's businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Elements of this press release contain or may contain inside information about Wolters Kluwer within the meaning of Article 7(1) of the Market Abuse Regulation (596/2014/EU). Trademarks referenced are owned by Wolters Kluwer N.V. and its subsidiaries and may be registered in various countries. Attachment 2025.06.05 Share Buyback Transactions May 29 - Jun 4 2025Sign in to access your portfolio
Yahoo
03-06-2025
- Business
- Yahoo
Jacobi Bitcoin ETF's Lowers Entry Barriers Allowing European Retail Investors to Jump In
Jacobi Asset Management has lowered entry barriers for its bitcoin BTC exchange-traded fund (ETF), allowing European retail investors to participate for the first time. This follows the removal of professional-only and minimum investment requirements by the Guernsey regulator. Originally launched in 2023 on Euronext Amsterdam, the ETF was designed to meet institutional grade standards for security, transparency, and compliance. Until now, access was limited to professional investors in line with regulatory requirements and market maturity. However, with the evolving financial ecosystem and growing institutional and governmental acceptance of bitcoin, Jacobi has worked closely with partners including Collas Crill, Midshore Consulting, and Sigma Asset Management to secure the removal of restrictions on retail participation. This strategic shift enables broader access to the ETF through regulated brokerage and investment platforms, subject to national regulations, significantly enhancing market inclusivity. The fund continues to be safeguarded by Zodia Custody, which provides secure institutional grade custody solutions. 'Our fund was designed from day one with a regulated, institutional-grade structure that investors could trust and were familiar with. Now, with greater regulatory alignment and growing public interest, we're delighted to expand access to all investors across eligible jurisdictions,' said Peter Lane, CEO of Jacobi Asset Management. "This marks a milestone not only for Jacobi, but also for Guernsey's positioning as a forward-looking digital asset jurisdiction," he added. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
